CN Patent

CN112679441A — 阿普昔腾坦的晶型、制备方法及其用途

Assigned to Seasons Biotechnology Taizhou Co Ltd · Expires 2021-04-20 · 5y expired

What this patent protects

本发明涉及阿普昔腾坦的多晶型、其制备方法及其用途。具体而言，本发明涉及N‑[5‑(4‑溴苯基)‑6‑[2‑[(5‑溴‑2‑嘧啶基)氧基]乙氧基]‑4‑嘧啶基]磺酰胺化合物的多晶型、制备方法及其用途。本发明公开了阿普昔腾坦的六种不同晶型、制备方法、其药物组合物以及其在制备用于治疗高血压、肺动脉高压等疾病的药物中的用途。

USPTO Abstract

本发明涉及阿普昔腾坦的多晶型、其制备方法及其用途。具体而言，本发明涉及N‑[5‑(4‑溴苯基)‑6‑[2‑[(5‑溴‑2‑嘧啶基)氧基]乙氧基]‑4‑嘧啶基]磺酰胺化合物的多晶型、制备方法及其用途。本发明公开了阿普昔腾坦的六种不同晶型、制备方法、其药物组合物以及其在制备用于治疗高血压、肺动脉高压等疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112679441A
Jurisdiction
CN
Classification
—
Expires
2021-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Seasons Biotechnology Taizhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.